 Wysłany: Śro 8:30, 30 Mar 2011 Temat postu: TORCH study brings the treatment of chronic obstru |
|
| _772,belstaff outlet
TORCH study brings the treatment of chronic obstructive pulmonary disease What is Enlightenment? Medical information. However, TORCH study did not show consistent results with the SMART study. In the TORCH study, there are 1521 cases of patients receiving treatment for 3 years LABA alone, its all-cause mortality was only 13.5%, even lower than the placebo group, 15.2%. Although no significant difference between two groups of mortality, but the results can explain at least 3 years alone LABA treatment of COPD does not increase the risk of death. By LaVecchia and other _3j view, LABA and even protection. Some of the results of TORCH that salmeterol is a winner, and fluticasone losers l5j. Although some of the evaluation is simple, but raises a serious question whether we need to re-evaluate the treatment of ICS in COPD status? The main reason for using the ICS evidence based medicine ICS can reduce the rate of acute exacerbation of COPD, improve patient quality of life. However, in theory, ICS on neutrophil airway inflammation of COPD is not valid, point of view from clinical practice will not affect the ICS the natural course of COPD. Recent studies have shown, ICS reduce the acute exacerbation of COPD and COPD seems to be mainly associated with eosinophilic airway inflammation _6j. Therefore, ICS treatment of COPD, the benefits are limited. TORCH study did not show long-term treatment of COPD LABA has a negative result. While LABA treatment can not reduce COPD mortality, but it reduces the rate of acute exacerbations and improve lung function and quality of life similar to the role and ICS, was significantly better than placebo. These results are significant differences in SMART study, in which the reasons for that? Is the difference in the disease, ethnic differences, or the number of cases too small TORCH study? These issues remain to be more clinical trials to verify. In short, despite the TORCH study did not achieve the expected purpose, but there is still a milestone. It is the first time that COPD mortality endpoint drug intervention of large-scale multi-center trial. COPD is a |
|
